Alan Cuthbertson PhD

Alan Cuthbertson is Head of Thorium Research at Bayer AS with responsibility for the development of a new class of alpha-particle emitting targeted antibody conjugate for the treatment of cancer. He joined Bayer through the acquisition and integration of Algeta ASA where he served as SVP R&D with the goal translating the targeted thorium-227 conjugate (TTC) platform from research to clinical phase, a role he continues with today. Alan was previously Head of Global Chemistry R&D at GE Healthcare working with the development of novel radiopharmaceuticals for a variety of medical diagnostic applications. He has a PhD in Chemistry from The University of Edinburgh.